Skip to main content

Table 3 Patient and cycle characteristics

From: Is letrozole during ovarian stimulation useful in breast cancer patients undergoing fertility preservation to reduce early luteal progesterone levels following GnRH-agonist trigger?

 

COSTLES group

Control group

p-value

 

n = 84

n = 162

 

Age (years)a

31.7 ± 0.4

32.7 ± 0.5

0.17

BMI (kg/m2)a

23.6 ± 0.5

23.4 ± 0.4

0.73

Antral follicle counta

22.0 ± 1.7

22.2 ± 1.0

0.93

AMH (ng/mL)a

2.6 ± 0

2 3.1 ± 0.3

0.18

GnRH antagonist starting daya

5.9 ± 0

25 5.8 ± 0.1

0.64

number of days of stimulationa

10.4 ± 0

2 10.8 ± 0.2

0.10

Total FSH dose (IU)a

2981 ± 237

3168 ± 252

0.30

Number of oocytes recovereda

14.2 ± 0.7

14.0 ± 0.8

0.91

Ocytesa

10.1 ± 0.6

11.1 ± 0.7

0.28

Number of frozen embryosa

7.0 ± 4.3

4.2 ± 2.9

0.20

  1. Abbreviations: AMH anti-Müllerian hormone, BMI body mass index, GnRH gonadotropin releasing hormone, IU international unity, SD standard deviation
  2. amean ± S